Indoco Remedies Limited (Indoco), a fully integrated pharma enterprise with a robust global presence, announced a groundbreaking partnership with the UK-based company, Clarity Pharma. This strategic alliance represents a pivotal event for Indoco, as it plans to release approximately 20 products into the UK market via Clarity Pharma over the upcoming 18 months. Simultaneously, Indoco will maintain supply to its clients under current B2B agreements.
Aditi Panandikar, the managing director of Indoco Remedies Ltd., remarked, “Our collaboration with Clarity Pharma is a vital step forward for Indoco, fortifying our standing in the UK pharmaceutical sector. By merging Indoco’s extensive array of top-notch, cost-effective pharmaceuticals with Clarity Pharma’s comprehensive distribution framework and market insight, we are set to deliver groundbreaking healthcare solutions to an expanded patient audience.”
Commenting on the partnership, Steve Soper, CEO of Clarity Pharma, stated, “Today marks the commencement of a thrilling chapter between Indoco and Clarity, culminating from years of dedicated effort in assembling this market access venture. The spectrum of Indoco products is both thrilling and comprehensive, promising substantial savings once launched. We anticipate a prosperous future of cooperation, advancement, and impact on medicine affordability.”
Indoco is a truly integrated, research-driven pharmaceutical company with an impressive global reach. With revenues amounting to US$ 212 million, the company employs over 6,000 individuals, including more than 400 proficient scientists and field personnel who form the backbone of the enterprise.
Clarity Pharma boasts over two decades and a half of expertise in market product introduction, currently serving over 4,000 primary healthcare clients. Indoco, with its significant global reach, matches well with Clarity’s extensive experience and established client base.